NVO vs. LLY
Compare and contrast key facts about Novo Nordisk A/S (NVO) and Eli Lilly and Company (LLY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NVO or LLY.
Correlation
The correlation between NVO and LLY is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NVO vs. LLY - Performance Comparison
Loading data...
Key characteristics
NVO:
-1.19
LLY:
-0.15
NVO:
-1.70
LLY:
0.07
NVO:
0.78
LLY:
1.01
NVO:
-0.82
LLY:
-0.21
NVO:
-1.52
LLY:
-0.41
NVO:
32.23%
LLY:
12.70%
NVO:
42.49%
LLY:
38.33%
NVO:
-71.29%
LLY:
-68.27%
NVO:
-55.28%
LLY:
-25.21%
Fundamentals
NVO:
$289.83B
LLY:
$669.76B
NVO:
$3.53
LLY:
$12.32
NVO:
18.53
LLY:
60.56
NVO:
0.98
LLY:
1.10
NVO:
0.96
LLY:
13.67
NVO:
13.94
LLY:
41.83
NVO:
$303.14B
LLY:
$49.00B
NVO:
$255.65B
LLY:
$40.03B
NVO:
$154.08B
LLY:
$16.67B
Returns By Period
In the year-to-date period, NVO achieves a -23.92% return, which is significantly lower than LLY's -7.15% return. Over the past 10 years, NVO has underperformed LLY with an annualized return of 10.77%, while LLY has yielded a comparatively higher 27.99% annualized return.
NVO
-23.92%
-2.50%
-38.78%
-50.58%
17.02%
10.77%
LLY
-7.15%
-5.14%
-11.56%
-5.73%
36.76%
27.99%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NVO vs. LLY — Risk-Adjusted Performance Rank
NVO
LLY
NVO vs. LLY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
NVO vs. LLY - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 2.50%, more than LLY's 0.75% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 2.50% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
LLY Eli Lilly and Company | 0.75% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% | 2.84% |
Drawdowns
NVO vs. LLY - Drawdown Comparison
The maximum NVO drawdown since its inception was -71.29%, roughly equal to the maximum LLY drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for NVO and LLY. For additional features, visit the drawdowns tool.
Loading data...
Volatility
NVO vs. LLY - Volatility Comparison
The current volatility for Novo Nordisk A/S (NVO) is 14.74%, while Eli Lilly and Company (LLY) has a volatility of 22.06%. This indicates that NVO experiences smaller price fluctuations and is considered to be less risky than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
NVO vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVO vs. LLY - Profitability Comparison
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported a gross profit of 65.20B and revenue of 78.09B. Therefore, the gross margin over that period was 83.5%.
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported a gross profit of 10.50B and revenue of 12.73B. Therefore, the gross margin over that period was 82.5%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported an operating income of 38.79B and revenue of 78.09B, resulting in an operating margin of 49.7%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported an operating income of 5.41B and revenue of 12.73B, resulting in an operating margin of 42.5%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported a net income of 29.03B and revenue of 78.09B, resulting in a net margin of 37.2%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported a net income of 2.76B and revenue of 12.73B, resulting in a net margin of 21.7%.